Circulating MicroRNAs as Novel Potential Biomarkers for Early Diagnosis of Acute Stroke in Humans

Wang, Wanhua; Sun, Guan; Zhang, Luyuan; Shi, Lei; Zeng, Yanjun

doi:10.1016/j.jstrokecerebrovasdis.2014.06.002

Cited by 83 publications

(58 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The sensitivity and specificity of miR-16 reached 100% and 91.3% in patients with large artery atherosclerosis. In previous studies of the change of circulating blood miRNAs after cerebral infarction, AUC values ranged from 0.642 to 0.999, sensitivity ranged from 80% to 88.3%, and specificity ranged from 41.1% to 94% [18–20]. The sensitivity of this study was relatively high, but the samples included in this study were all taken from HACI patients within 6 hours of infarction onset.…”

Section: Discussionmentioning

confidence: 81%

Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction

Tian

Yang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

Indices for the diagnosis of hyperacute cerebral infarction (HACI) and the prediction of prognosis are essential for timely and appropriate management. MicroRNAs (miRNAs) that regulate gene expression following stroke have potential use as prognostic markers of HACI. Here, we explored whether concentrations of circulating miRNAs correlate with clinical outcomes and thus form a system of stroke stratification. Plasma samples from patients with HACI (n = 7) and age-matched healthy volunteers (HVT, n = 4) were screened by microarray to find differentially expressed miRNAs, some of which were further verified by quantitative reverse transcription polymerase chain reaction (qRT-PCR) (HACI:HVT = 33:23). The target genes of the miRNAs with verified differential expression were investigated by GO and KEEG analyses. Using the TOAST (OCSP) criteria and the 3-month modified Rankin Score (mRS), relationships among the expression patterns of specific miRNAs, stroke stratification, and clinical prognosis were determined. The microarray analysis revealed 12 differentially expressed miRNAs. Among seven selected miRNAs verified with qRT-PCR, miR-16 expression in the HACI group was the most significantly different from the HVT group (P < 0.01). Bioinformatics analysis showed that the potential target genes of miR-16 were mainly involved in programmed cell death and the p53 signaling pathways. Receiver operating characteristic (ROC) analysis showed that the area under the curve (AUC) of miR-16 was 0.775 (sensitivity 69.7% and specificity 87%) and 0.952 (sensitivity 100% and specificity 91.3%) in overall patients and patients with large artery atherosclerosis (LAAS), respectively. Elevated miR-16 expression was associated with the stroke subtype of LAAS, total anterior circulation infarction, partial anterior circulation infarction, and poor prognosis (P < 0.05). A diagnostic method based on rapid measurement of plasma miR-16 has the potential to identify hyperacute cerebral infarction with LAAS with high sensitivity and specificity, which would inform and improve early treatment decisions and disease management.

show abstract

Section: Discussionmentioning

confidence: 81%

Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction

Tian

Yang

et al. 2016

PLoS ONE

View full text Add to dashboard Cite

show abstract

“…Circulating hsa-miR-4306 was shown to be elevated in patients with acute stroke, whereas circulating hsa-miR-320e and hsa-miR-320d were reduced in patients compared with healthy individuals [29]. It has been proposed that hsa-miR-4306, hsa-miR-320e and hsa-miR-320d in plasma may serve as novel biomarkers for the early detection of acute stroke in humans [29].…”

Section: Discussionmentioning

confidence: 99%

“…It has been proposed that hsa-miR-4306, hsa-miR-320e and hsa-miR-320d in plasma may serve as novel biomarkers for the early detection of acute stroke in humans [29]. miR-4306 were was shown to be significantly downregulated both in Cellular Physiology and Biochemistry Cellular Physiology and Biochemistry plasma and in sclerotic samples of patients with arteriosclerosis obliterans compared with controls [30].…”

Section: Discussionmentioning

confidence: 99%

Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine

Yang

Chen

et al. 2018

Cell Physiol Biochem

View full text Add to dashboard Cite

Background/Aims: Circulating miRNAs could serve as biomarkers for diagnosis or prognosis of heart diseases and cerebrovascular diseases. Dexmedetomidine has protective effects in various organs. The effects of dexmedetomidine on circulating miRNAs remain unknown. Here, we investigated differentially expressed miRNA and to predict the target genes of the miRNA in patients receiving dexmedetomidine. Methods: The expression levels of circulating miRNAs of 3 patients were determined through high through-put miRNA sequencing technology. Target genes of the identified differentially expressed miRNAs were predicted using TargetScan 7.1 and miRDB v.5. Gene Ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) were used to conduct functional annotation and pathway enrichment analysis of target genes respectively. Results: Twelve differentially expressed miRNAs were identified. Five miRNAs were upregulated (hsa-miR-4508, hsa-miR-novel-chr8_87373, hsa-miR-30a-3p, hsa-miR-novel-chr16_26099, hsa-miR-4306) and seven miRNAs (hsa-miR-744-5p, hsa-miR-320a, hsa-miR-novel-chr9_90035, hsa-miR-101-3p, hsa-miR-150-5p, hsa-miR-342-3p, and hsa-miR-140-3p) were downregulated after administration of dexmedetomidine in the subjects. The target genes and pathways related to the differentially expressed miRNAs were predicted and analyzed. Conclusion: The differentially expressed miRNAs may be involved in the mechanisms of action of dexmedetomidine. Specific miRNAs, such as hsa-miR-101-3p, hsa-miR-150-5p and hsa-miR-140-3p, are new potential targets for further functional studies of dexmedetomidine.

show abstract

“…Wang et al (2014) studied circulating miRNAs in blood plasma from subjects with acute stroke and control subjects to determine whether circulating miRNAs can serve as possible biomarkers for acute stroke in humans [33]. Using miRNA microarrays and real-time PCR analyses, they found that hsa-miR-106b-5P and hsa-miR-4306 were present in high abundance in patients of acute stroke, whereas hsa-miR- 320e and hsa-miR- 320d were present in low abundance in control subjects.…”

Section: Mirnas As Biomarkers In Strokementioning

confidence: 99%

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Vijayan

Reddy

2016

Biochimica et Biophysica Acta (BBA) - Molecular Basis of Diseas

101

View full text Add to dashboard Cite

Stroke is the second leading cause of death in the world. Stroke occurs when blood flow stops, and that stoppage results in reduced oxygen supply to neurons in the brain. The occurrence of stroke increases with age, but anyone at any age can suffer from stroke. Recent research has implicated multiple cellular changes in stroke patients, including oxidative stress and mitochondrial dysfunction, inflammatory responses, and changes in mRNA and proteins. Recent research has also revealed that stroke is associated with modifiable and non-modifiable risk factors. Stroke can be controlled by modifiable risk factors, including diet, cardiovascular, hypertension, smoking, diabetes, obesity, metabolic syndrome, depression and traumatic brain injury. Stroke is the major risk factor for vascular dementia (VaD) and Alzheimer’s disease (AD). The purpose of this article is to review the latest developments in research efforts directed at identifying 1) latest developments in identifying biomarkers in peripheral and central nervous system tissues, 2) changes in microRNAs (miRNAs) in patients with stroke, 3) miRNA profile and function in animal brain, and 4) protein biomarkers in ischemic stroke. This article also reviews research investigating circulatory miRNAs as peripheral biomarkers of stroke.

show abstract

Circulating MicroRNAs as Novel Potential Biomarkers for Early Diagnosis of Acute Stroke in Humans

Cited by 83 publications

References 14 publications

Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction

Plasma MicroRNA-16 Is a Biomarker for Diagnosis, Stratification, and Prognosis of Hyperacute Cerebral Infarction

Circulating miRNA Expression Profiling and Target Prediction in Patients Receiving Dexmedetomidine

Peripheral biomarkers of stroke: Focus on circulatory microRNAs

Contact Info

Product

Resources

About